profit from every $100 of sales.
$0$100
ClearPoint Neuro
$8.48-0.12% today
-45.3% in 1 year
1-year low $8.481-year high $19.43
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What ClearPoint Neuro sold, what it kept, and what it did with the cash.
Sales went from $20.6 million in 2022 to $37.0 million in 2025, with -$25.5 million of profit last year.
SalesProfit
ClearPoint Neuro vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| ClearPoint Neuro | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads ClearPoint Neuro's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 21 | 24 | 31 | 37 | |
| 14 | 14 | 19 | 23 | |
| -16 | -22 | -20 | -24 | |
| -16 | -21 | -16 | -21 | |
| -16 | -22 | -19 | -26 | |
| -0.68 | -0.90 | -0.70 | -0.90 | |
| 65.8% | 56.8% | 60.9% | 61.4% | |
| -79.5% | -93.7% | -62.9% | -65.4% | |
| -80.0% | -92.2% | -60.3% | -69.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 55 | 43 | 39 | 98 |
| Cash | 28 | 23 | 20 | 46 |
| Total debt | 12 | 14 | 4 | 58 |
| Total liabilities | 19 | 21 | 14 | 70 |
| 37 | 21 | 25 | 28 | |
| 24 | 25 | 27 | 28 | |
| -26.4% | -50.5% | -50.2% | -21.2% | |
| -44.6% | -104.3% | -74.5% | -91.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -16 | -14 | -9 | -24 | |
| 1 | 1 | 0 | 1 | |
| -17 | -15 | -9 | -24 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 4 | 6 | 7 | 8 |
Valuation
- –
- –
- –
- 17.5×
- 7.4×
- –
- –
- -9.0%
- -9.4%
- 0.0%
Profitability
- 61.4%
- -65.4%
- -69.1%
- -58.9%
- -31.5%
- -43.0%
- -141.0%
- -31.1%
- -31.5%
- 37.0%
Growth
- +21.6%
- –
- −165.0%
- –
- +8.1%
Financial health
- –
- 3.37
- 68.1%
- -9.8×
- 5.79
- 4.88
- 0.43
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 946
Bottom 6%of 871
Top 27%of 867
Bottom 13%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.32 | -0.28 | −14.3% |
| Mar 17, 2026 | -0.27 | -0.22 | −22.7% |
| Nov 6, 2025 | -0.21 | -0.20 | −5.0% |
| Aug 12, 2025 | -0.21 | -0.20 | −5.0% |
| May 13, 2025 | -0.22 | -0.15 | −46.7% |
| Feb 26, 2025 | -0.20 | -0.15 | −33.3% |
| Nov 7, 2024 | -0.18 | -0.17 | −5.9% |
| Aug 7, 2024 | -0.16 | -0.19 | +15.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
20No pass
Philip Fisher
47No pass
Peter Lynch
37No pass
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
43No pass
Questions about ClearPoint Neuro
Is ClearPoint Neuro a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the ClearPoint Neuro AI analysis
What does ClearPoint Neuro do?
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It is in Medical - Devices.
Does ClearPoint Neuro pay a dividend?
No. ClearPoint Neuro does not pay a dividend at the moment.
Is ClearPoint Neuro stock halal?
Yes. ClearPoint Neuro passes our halal screen: its business is permitted and its debt is 21% of its market value, under the 30% limit. How we check
How has ClearPoint Neuro stock done over the past year?
Down 45.3% over the past twelve months, to $8.48. It traded between $8.48 and $19.43 and is 56.4% below its high.
Who are ClearPoint Neuro's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with ClearPoint Neuro's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.